Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harb Perspect Med. 2018;8(10).

Nayar R, Barkan GA, Benedict C, Booth C, Chhieng DC, Mody D, et al. Laboratory management curriculum for cytopathology subspecialty training. J Am Soc Cytopathol. 2018;7(2):61-78.

Curtis BR, Hsu Y-, Podoltsev N, Lacy J, Curtis S, Samuel MS, et al. Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. Blood. 2018;131(13):1486-1489.

Yang RK, Nazeef M, Patel SS, Mattison R, Yang DT, Ranheim EA, et al. Improving bone marrow biopsy quality through peer discussion and data comparisons: A single institution experience. Int J Lab Hematol. 2018;40(4):419-426.

Ruder B, Murtadak V, Stürzl M, Wirtz S, Distler U, Tenzer S, et al. Chronic intestinal inflammation in mice expressing viral Flip in epithelial cells. Mucosal Immunol. 2018;11(6):1621-1629.

de Brot S, Robinson BD, Scase T, Grau-Roma L, Wilkinson E, Boorjian SA, et al. The dog as an animal model for bladder and urethral urothelial carcinoma: Comparative epidemiology and histology. Oncol Lett. 2018;16(2):1641-1649.

Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, et al. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Sci Rep. 2018;8(1):7189.

Johncilla M, Jessurun J, Brown I, Hornick JL, Bellizzi AM, Shia J, et al. Are Enterocolic Mucosal Mast Cell Aggregates Clinically Relevant in Patients Without Suspected or Established Systemic Mastocytosis? Am J Surg Pathol. 2018;42(10):1390-1395.

Ooki A, Dinalankara W, Marchionni L, Tsay J-, Goparaju C, Maleki Z, et al. Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma. Oncogene. 2018;37(45):5967-5981.

Hartono C, Chung M, Perlman AS, Chevalier JM, Serur D, Seshan SV, et al. Bortezomib for Reduction of Proteinuria in IgA Nephropathy. Kidney Int Rep. 2018;3(4):861-866.